Performance of CD3xCD19 Bispecific Monoclonal Antibodies in B Cell Malignancy

References

• Veerman A. J. P., Pieters R. Annotation: Drug sensitivity assays in leukaemia and lymphoma. Br. J. Haemat. 1990; 74: 381–384
   PubMed Web of Science ®Google Scholar
• Foon K. A. Biological Response Modifiers: The New Immunotherapy. Cancer Res. 1989; 49: 1621–1639
   PubMed Web of Science ®Google Scholar
• Lotze M. T., Finn O. J. Recent advances in cellular immunology: implications for immunity to cancer. Immunol. Today 1990; 11: 190–193
   PubMedGoogle Scholar
• Heaton K. M., Grimm E. A. Cytokine combinations in immunotherapy for solid tumors: a review. Cancer Immunol. Immunother. 1993; 37: 213–219
   PubMed Web of Science ®Google Scholar
• Maas R. A., Dullens H. F. J., den Otter W. Interleukin-2 in cancer treatment: disappointing or (still) promising? A review. Cancer Immunol. Immunother. 1993; 36: 141–148
   PubMed Web of Science ®Google Scholar
• Smith K. A. Lowest dose Interleukin-2 immunotherapy. Blood 1993; 81: 1414–1423
   PubMed Web of Science ®Google Scholar
• Old L. J. Tumor Necrosis Factor (TNF). Science 1985; 230: 630–632
   PubMed Web of Science ®Google Scholar
• Lotze M. T., Line B. R., Mathisen D. J., Rosenberg S. A. The in vivo distribution of autologous human and murine lymphoid cells grown in T cell growth factor (TCGF): implications for the adoptive immunotherapy of tumors. J. Immunol. 1980; 125: 1487–1493
   PubMed Web of Science ®Google Scholar
• Takai N., Tanaka R., Yoshida S., Hara N., Saito T. In vivo and in vitro effect of adoptive immunotherapy of experimental murine brain tumors using lymphokine-activated killer cells. Cancer Res. 1988; 48: 2047–2052
   PubMed Web of Science ®Google Scholar
• Hamann A. Mechanisms of lymphocyte traffic and cell targeting. Int. J. Cancer 1992; 7: 19–23
   Google Scholar
• Rosenberg S. A. Immunotherapy of cancer using interleukin-2: current status and future prospects. Immunol. Today 1988; 9: 58–62
   PubMedGoogle Scholar
• Whiteside T. L., Miescher S., Hurlimann J., Moretta L., von Fliedner V. Separation, phenotyping and limiting dilution analysis of T-lymphocytes infiltrating human solid tumors. Int. J. Cancer 1986; 37: 803–811
   PubMed Web of Science ®Google Scholar
• Rosenberg S. A., Packard B. S., Aebersold P. M., Solomon D., Topalian S. L., Toy S. T., Simon P., Lotze M. T., Yang J. G., Seipp C. A., Simpson C., Carter C., Bock S., Schwartzentruber D., Wei J. P., White D. E. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N. Engl. J. Med. 1988; 319: 1676–1680
   PubMed Web of Science ®Google Scholar
• Grossbard M. L., Press O. W., Appelbaum F. R., Bernstein I. D., Nadler L. M. Monoclonal antibody-based therapies of leukemia and lymphoma. Blood 1992; 80: 863–878
   PubMed Web of Science ®Google Scholar
• Mellstedt H. Monoclonal antibodies in cancer therapy. Curr. Opin. Immunol. 1990; 2: 708–713
   Web of Science ®Google Scholar
• Uckun F. M., Chelstrom L. M., Finnegan D., Tuel-Ahlgren L., Manivel C., Irvin J. D., Myers D. E., Gunther R. Effective immunochemotherapy of Calla+Cμ+ human pre-B acute lympfoblastic leukemia in mice with severe combined immunodeficiency using B43 (anti-CD19) pokeweedl antiviral protien im-munotoxin plus cyclophosphamide. Blood. 1992; 79: 3116–3129
   PubMed Web of Science ®Google Scholar
• Ghetie M. A., Tucker K., Richardson J., Uhr J. W., Vitetta E. S. The antitumor activity of an anti-CD22 immunotoxin in SCID mice with disseminated Daudi lymphoma is enhanced by either an antiLCD 19 antibody or an anti-CD 19 immunotoxin. Blood 1992; 80: 2315–2320
   PubMed Web of Science ®Google Scholar
• Rosen S. T., Zimmer A. M., Goldman-Leikin R., Gordon L. I., Kazikiewicz J. M., Kaplan E. H., Variakoijs D., Marder R. J., Dykewicz M. S., Piergies A., Silverstein E. A., Roenigk H. H., Spies S. M. Radioimmunodetection and radioimmunotherapy of cutaneous T cell lymphomas using an 131 I-labeled monoclonal antibody; an Illinois Cancer Council study. J. Clin. Oncol. 1987; 5: 562–573
   PubMed Web of Science ®Google Scholar
• Vriesendorp H. M., Herpst J. M., Germack M. A., Klein J. L., Leichner P. K., Loudenslager D. M., Order S. E. Phase I—II studies of Yttrium-labeled antiferritin treatment for end-stage Hodgkin's disease, including radiation therapy oncology group 87–01. J. Clin. Oncol. 1991; 9: 918–928
   PubMed Web of Science ®Google Scholar
• Köhler G., Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256: 495–497
   PubMed Web of Science ®Google Scholar
• Goding J. W. Antibody production by hybridomas. J. Immunol. Methods 1980; 39: 285–308
   PubMed Web of Science ®Google Scholar
• Köhler G. Derivation and divenification of monoclonal antibodies. EMBO J. 1985; 4: 1359–1365
   PubMed Web of Science ®Google Scholar
• Bispecific antibodies and targeted cellular, cytotoxicity. Lienhart, Les UlisFrance 1991; VII
   Google Scholar
• Staerz U. D., Bevan M. J. Use of anti-receptor antibodies to focus T-cell activity. Immunol. Today 1986; 7 & 8: 241–254
   Google Scholar
• Perez P., Hoffman R. W., Shaw S., Bluestone J. A., Segal D. M. Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody. Nature 1985; 316: 354–356
   PubMed Web of Science ®Google Scholar
• Tutt A., Greenman J., Stevenson G. T., Glennie M. J. Bispecific F(ab'y)3 antibody derivatives for redirecting unprimed cytotoxic Tcells. Eur. J. Immunol. 1991; 21: 1351–1358
   PubMed Web of Science ®Google Scholar
• Karpovsky B., Titus J. A., Stephany D. A., Segal D. M. Production of target-specific effector cells using hetero-cross-linked aggregates containing anti-target cell and anti-Fcγ receptor antibodies. J. Exp. Med. 1984; 160: 1686–1701
   PubMed Web of Science ®Google Scholar
• Milstein C., Cuello A. C. Hybrid hybridomas and the production of bi-specific monoclonal antibodies. Immunol. Today 1984; 5: 299–304
   PubMedGoogle Scholar
• De Lau W. B. M., van Loon A. E., Heije K., Valerio D., Bast B. J. E.G. Production of hybrid hybridomas based on HAT(s)-neomycin(r) double mutants. J. Immunol. Methods 1989; 117: 1–8
   PubMed Web of Science ®Google Scholar
• Lanzavecchia A., Scheidegger D. The use of hybrid hybridomas to target human cytotoxic T lymphocytes. Eur. J. Immunol. 1987; 17: 105–111
   PubMed Web of Science ®Google Scholar
• De Lau W. B. M., Heije K., Neefjes J. J., Oosterwegel M., Rozemuller E., Bast B. J. E.G. Absence of preferential homologous H/L chain association in hybrid hybridomas. J. Int. Immunol. 1991; 146: 906–914
   Google Scholar
• Chatenoud L., Bach J. F. Antigenic modulation—a major mechanism of antibody action. Immunol. Today 1984; 5: 20–25
   PubMedGoogle Scholar
• Kostelney S. A., Cole M. S., Tso J. Y. Formation of a bispecific antibody by the use of leucine zippers. J. Immunol. 1992; 148: 1547–1553
   PubMed Web of Science ®Google Scholar
• Weiner G. J., Kostelny S. A., Hillstrom J. R., Cole M. S., Link B. K., Wang S. L., Tso J. Y. The role of T cell activation in anti-CD3 × antitumor bispecific antibody therapy. J. Immunol. 1994; 152: 2385–2392
   PubMed Web of Science ®Google Scholar
• Hayden M. S., Linsley P. S., Gayle M. A., Bajorath J., Brady W. A., Norris N. A., Fell H. P., Ledbetter J. A., Gilliland L. K. Single-chain mono- and bispecific antibody derivatives with novel biological properties and antitumor activity from a COS cell transient expression system. Therapeutic Immunology 1994; 1: 3–15
   PubMedGoogle Scholar
• Traunecker A., Lanravecchia A., Karjalainen K. Janusin: new molecular design for bispecific reagents. Int. J. Cancer 1992; 7: 51–52
   Google Scholar
• Staerz U. D., Kanagawa O., Bevan M. J. Hybrid antibodies can target sites for attack by T cells. Nature 1985; 314: 628–630
   PubMed Web of Science ®Google Scholar
• Fanger M. W., Segal D. M., Romet-Lemonne J. L. Bispecific antibodies arid targeted cellular cytotoxicity. Immunol. Today 1991; 12: 51–54
   PubMedGoogle Scholar
• Fanger M. W., Guyre P. M. Bispecific antibodies for targeted cellular cytotoxicity. Tib Tech 1991; 9: 375–380
   PubMed Web of Science ®Google Scholar
• Fanger M. W., Morganelli P. M., Guyre P. M. Bispecific antibodies. Crit. Rev, Immunol. 1992; 12: 101–124
   PubMed Web of Science ®Google Scholar
• Beun G. D. M., van de Velde C. J. H., Fleuren G. J. T-cell based cancer immunotherapy: direct or redirect tumor-cell recognition?. Immunol Today 1994; 15: 11–15
   PubMedGoogle Scholar
• Segal D. M., Qian J. H, Mezzanzanica D., Garrido M. A., Titus J. A., George A. J. T., Jost C. R., Perez P., Wunderlich J. R. Targeting of anti-tumor responses with Bispecitic antibodies. Immunobiol. 1992; 185: 390–402
   PubMed Web of Science ®Google Scholar
• Glennie M. J., Stevenson G. T. Univalent antibodies kill tumour cells in vitro and in vivo. Nature 1982; 295: 712–713
   PubMed Web of Science ®Google Scholar
• Roosnek E., Lanzavecchia A. Triggering T cells by otherwise inert hybrid anti-CD3/antitumor antibodies requires encouter with the specific target cell. J. Exp. Med. 1989; 170: 297–302
   PubMed Web of Science ®Google Scholar
• Canevari S., Mezzanzanica D., Menard S., Ferrini S., Moretta L., Colnaghi M. I. Possible targets on carcinoma for BmAb retargeting of lymphocyte or drug cytotoxicity. Int. J. Cancer 1992; 7: 42–44
   Google Scholar
• Nitta T., Sato K., Okumura K., Ishii S. Induction of cytotoxicity in human T cells coated with anti-glioma × anti-CD3 bispecific antibody against human glioma cells. J. Neurosurg. 1990; 72: 476–481
   PubMed Web of Science ®Google Scholar
• Haagen J. A., van de Griend R., Clark M., Geerars A., Bast B., De Gast B. Killing of human leukaemia/lymphoma B cells by activated cytotoxic T lymphocytes in the presence of a Bispecific monoclonal antibody (αCD3/αCD19). Clin. Exp. Immunol. 1992; 90: 368–375
   PubMed Web of Science ®Google Scholar
• Anderson P. M., Crist W., Hasz D., Caroll A. J., Myers D. E., Uckun F. M. G19.4(αCD3) × B43(αCD19) monoclonal antibody heterconjugate triggers CD19 antigen-specific lysis of t(4;11) acute lymphoblastic CD3 antigen-positive cytotoxic T cells. Blood 1992; 80: 2826–2834
   PubMed Web of Science ®Google Scholar
• Malygin A. M., Somersalo K., Timonen T. Promotion of natural killer cell growth in vitro by bispecific (anti-CD3 × anti-CD16) antibodies. Immunology 1994; 81: 92–95
   PubMed Web of Science ®Google Scholar
• Ball E. D., Guyre P. M., Mills L., Fisher J., Dinces N. B., Fanger M. W. Initial trial of bispecific antibody-mediated immunotherapy of CD15-bearing tumors: cytotoxicity of human tumor cells using a bispecific antibody comprised of anti-CD15 (MoAb PM81) and anti-CD64/FcγRI (MoAb 32). J. Hematotherapy 1992; 1: 85–94
   PubMedGoogle Scholar
• Brissinck J., Demanet C., Moser M., Leo O., Thielemans K. Treatment of mice bearing BCL1 lymphoma with bispecific antibodies. J Immunol. 1991; 147: 4019–4026
   PubMed Web of Science ®Google Scholar
• Demanet C., Brissinck J., Mechelen M. V., Loe O., Thielemans K. Treatment of murine B cell lymphoma with bispecific monoclonal antibodies (anti-idiotype × anti-CD3). J. Immunol. 1991; 147: 1091–1097
   PubMed Web of Science ®Google Scholar
• Weiner G. J., Hillstrom J. R. Bispecific anti-idio-type/anti-CD3 antibody therapy of murine B cell lymphoma. J. Immunol. 1991; 147: 4035–4044
   PubMed Web of Science ®Google Scholar
• Bolhuis R. L. H., Lamers C. H. J., Gocy S. H., Eggermont A. M. M., Trimbos J. B. M.Z., Stoter G, Lanzavecchia A., De Re E., Miotti S., Raspagliesi F., Rivoltini L., Colnaghi M. I. Adoptive immunotherapy of ovarian carcinoma with Bs-Mab-targeted lymphocytes: a multicenter study. Int. J. Cancer 1992; supl. 7: 78–81
   Google Scholar
• Nitta T., Sato K., Yagita H., Okumura K., Ishii S. Preliminary trial of specific targeting therapy against malignant glioma. Lancer 1990; 335: 368–371
   PubMed Web of Science ®Google Scholar
• De Leij L., De Jonge M., ter Haar A., . Intrapleural and intraperitoneal application of bispecific antibody retargeted lymphocytes to cancer patients. Bispecific antibodies and targeted cellular cytotoxicity, J. L. Romet-Lemonne, M. W. Fanger Segal, et al. Les D. M. Ulis, LienhartFrance 1991; 249–253
   Google Scholar
• Kroesen B. J., Buter J., Sleijfer D., Th, Janssen R. A. J., van der Graaf W. T. A., The T. H., De Leij L., Mulder N. H. Phase I study of intravenously applied bispecific antibody in renal cell cancer patients receiving subcutaneous interleukin 2. Br. J. Cancer 1994; 70: 652–661
   PubMed Web of Science ®Google Scholar
• Clark M., Bolt S., Tunnacliffe A., Waldmann H. Use of bispecific monoclonal antibodies to treat hematological malignancies: a model system using CD3 transgenic mice. Bispecific antibodies and targeted cellular cytotoxicity, J. L. Romet-Lemonne, M. W. Fanger, D. M. Segal Les Ulis. Liehnart, France 1991; 243–247
   Google Scholar
• Friend P. J. Immunosuppression with monoclonal antibodies. Curr. Opin. Immunol. 1990; 2: 859–863
   Web of Science ®Google Scholar
• Stamenkovic I., Seed B. CD 19, the earliest differentiation antigen of the B cell lineage, bears three extracellular immunoglobulin-like domains and an Epstein-Barr virus-related cytoplasmic tail. J. Exp. Med. 1988; 168: 1205–1210
   PubMed Web of Science ®Google Scholar
• Zhou L. J., Ord D. C., Hughes A. L., Tedder T. F. Structure and domain organization of the CD 19 antigen of human, mouse, and guinea pig B lymphocytes. Conservation of the extensive cytoplasmic domain. J. Immunol. 1991; 147: 1424–1432
   PubMed Web of Science ®Google Scholar
• Bradbury L. E., Kansas G. S., Levy S., Evans R. L., Tedder T. F. The CD19/CD21 signal transducing complex of human B lymphocytes includes the target of antiproliferative antibody-I and Leu-13 molecules. J. Immunol. 1992; 149: 2841–2850
   PubMed Web of Science ®Google Scholar
• De Rie M. A., Schumacher T. N. M., van Schijndel G. M. W., van Lier R. A. W., Miedema F. Regulatory role of CD19 molecules in B-cell activation and differentiation. Cell. Immunol. 1989; 118: 368–381
   PubMed Web of Science ®Google Scholar
• Rigley K. P., Callard R. E. Inhibition of B cell proliferation with anti-CD19 monoclonal antibodies: anti-CD19 antibodies do not interfere with early signaling events triggered by anti-IgM or interleukin. Eur. J. Immunol. 1991; 21: 535–540
   PubMed Web of Science ®Google Scholar
• Carter R. H., Fearon D. T. CD19: lowering the tresh-old for antigen receptor stimulation of B lymphocytes. Science 1992; 256: 105–107
   PubMed Web of Science ®Google Scholar
• Ghetie M. A., Picker L. J., Richardson J. A., Tucker K., Uhr J. W., Vitetta E. S. Anti-CD19 inhibits the growth of human B-cell tumor lines in vitro and of Daudi cells in SCID mice by inducing cell cycle arrest. Blood 1994; 83: 1329–1336
   PubMed Web of Science ®Google Scholar
• Uckun F. M., Ledbetter J. A. Immunobiologic differences between normal and leukemic human B-cell precursors. Proc. Natl. Acad. Sci. USA 1988; 85: 8603–8607
   PubMed Web of Science ®Google Scholar
• Uckun F. M. Regulation of human B-cell ontogeny. Blood 1990; 76: 1908–1923
   PubMed Web of Science ®Google Scholar
• Hekman A., Honselaar A., Sein J. J., Rodenhuis S., De Rie M., Vuist W., Melief C. J. M., Rumke Ph. Treatment of human B-cell lymphoma with anti-CD19 monoclonal antibody and with a combination of anti-CD 19 and IL-2. Mechanisms of Action rind Therapeutic Applications of Biologicals in Cancer 1989; 293–303
   Google Scholar
• Hekman A., Honselaar A., Vuist W. M. J., Sein J. J., Rodenhuis S., ten Bokkel Huinink W. W., Somers R., Rumke Ph., Melief C. J. M. Initial experience with treatment of human B cell lymphoma with anti-CD 19 monoclonal antibody. Cancer Immunol. Immunother. 1991; 32: 364–372
   PubMed Web of Science ®Google Scholar
• Uckun F. M., Manivel C., Arthur D., Chelstrom L. M., Finnegan D., Tuel-Ahlgren L., Irvin J. D., Myers D. E., Gunther R. In vivo efficacy of B43(anti-CD19)-pokeweedantiviral protien immunotoxin against human pre-B cell acute lymphoblastic leukemia in mice with severe combined immunodeficiency. Blood 1992; 79: 2201–2214
   PubMed Web of Science ®Google Scholar
• Pulczynski S., Boesen A. M., Jensen O. M. Antibody-induced modulation and intracellular transport of CD10 and CD19 antigens in Human B-cell lines: An immuno-fluorescence and immunoelectron microscopy study. Blood 1993; 81: 1549–1557
   PubMed Web of Science ®Google Scholar
• De Rie M. A., Zeijlemaker W. P., van de Borne A. E. G.K. Inhibition, by vinca alkaloids and colchicine, of antigenic modulation induced by anti-CD19 monoclonal antibodies. Leukemia Res. 1988; 12: 135–141
   PubMed Web of Science ®Google Scholar
• Clayton L. K., Lerner A., Diener A. C., Hussey R. E., Koyasu S., Reinherz E. L. T-cell-receptor isoforms. Int. J. Cancer 1992; 7: 1–5
   Google Scholar
• Chen L., Linsley P. S., Hellström K. E. Costimulation of T cells for tumor immunity. Immunol. Today 1993; 14: 483–486
   PubMedGoogle Scholar
• Lamers C. H. J., van de Griend R. J., Braakman E., Ronteltap C. P. M., Benard J., Stoter G., Gratama J. W., Bolhuis R. L. H. Optimization of culture conditions for activation and large-scale expansion of human T lymphocytes for bispecific antibody-directed cellular immunotherapy. Int. J. Cancer 1992; 51: 973–979
   PubMed Web of Science ®Google Scholar
• Uberti J. P., Joshi I., Ueda M., Martilotti F., Sensenbrenner L. L., Lum L. G. Preclinical studies using immobilized OKT3 to activate human T cells for adoptive immunotherapy: optimal conditions for the proliferation and induction of non-MHC-restricted cytotoxicity. Cancer Immunol. Immunopathol. 1994; 70: 234–240
   Web of Science ®Google Scholar
• van de Winkel J. G. J., Capel P. J. A. Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications. Immunol. Today 1993; 14: 215–221
   PubMedGoogle Scholar
• Brüggemann M. Evolution of the rat immunoglobulin γ heavy-chain gene family. Gene 1988; 74: 473–482
   PubMed Web of Science ®Google Scholar
• Norman D. J., Chatenoud L., Cohen D., Goldman M., Shield C. F. Consensus statement regarding OKT3-induced cytokine-release syndrome and human antimouse antibodies. Transplantation Proceedings 1993; 25: 89–92
   PubMed Web of Science ®Google Scholar
• Parlevliet K. J., Jonker M., ten Berge R. J. M., van Lier R. A. W., Wilmink J. M., Strengers P. F. W., Aarden L. A., Th P., Schellekens A. Anti-CD3 murine monoclonal iso-type swith variants tested for toxicity and immunologic monitoring in four chimpanzees. Transplantation 1990; 50: 889–892
   PubMed Web of Science ®Google Scholar
• Debets J. M. H., van de Winkel J. G. J., Ceuppens J. L., Dieteren I. E. M., Buurman W. A. Cross-linking of both FcγRI and FcγRII induces secretion of tumor necrosis factor by human monocytes, requiring high affinity Fc-FcγR interactions. J. Immunol. 1990; 144: 1304–1310
   PubMed Web of Science ®Google Scholar
• Duits A. J., Aarden L. A., Ernst L. K., Capel P. J. A., van de Winkel J. G. J. Isotype-specific cross-linking of select human Fcγ-Receptor isoforms triggers release of IL-6. Clin. Exp. Immunol. 1993; 92: 225–231
   PubMed Web of Science ®Google Scholar
• van Lier R. A. W., Boot J. H. A., Verhoeven A. J., De Groot E. R., Brouwer M., Aarden L. A. Functional studies with anti-CD3 heavy chain isotype switch-variant monoclonal antibodies: Accessory cell-independent induction of interleukin-2 responsiveness in T cell by ε-anti-CD3. J. Immunol. 1987; 139: 2873–2879
   PubMed Web of Science ®Google Scholar
• Parren P. W. H.I., Warmerdam P. A. M., Boeije L. C. M., Capel P. J. A., van de Winkel J. G. J., Aarden L. A. Characterization of IgG FcR-mediated proliferation of human T cells induced by mouse and human anti-CD3 monoclonal antibodies. J. Immunol. 1992; 148: 695–701
   PubMed Web of Science ®Google Scholar
• Kaneoka H., Perez-Rojas G., Sasasuki T., Benike C. J., Engleman E. G. Human T lymphocyte proliferation induced by a pan-T monoclonal antibody (anti-leu 4): heterogeneity of response is a function of monocytes. J. Immunol. 1983; 131: 158–164
   PubMed Web of Science ®Google Scholar
• Koolwijk P., Spierenburg G. T., Frasa H., Boot J. H. A., van de Winkel J. G. J., Bast B. J. E.G. Interaction between hybrid mouse monoclonal antibodies and the human high-affinity IgG FcR, huFcγRI, on U937. J. Immunol. 1989; 143: 1656–1662
   PubMed Web of Science ®Google Scholar
• Clark M., Bindon C., Dyer M., Friend P., Hale G., Cobbold R., Calne H., Waldmann H. The improved lytic function and in vivo efficacy of monovalent monoclonal CD3 antibodies. Eur. J. Immunol. 1989; 19: 381–388
   Google Scholar
• Haagen I. A., Geerars A. J. G., Bast B. J. E.G., De Cast G. C., van de Winkel J. G. J., De Lau W. B. M. Evaluation of Fcγ receptor mediated T cell activation by two purified CD3×CD19 bispecific monoclonal antibodies with hybrid Fc domains. Therapeutic Immunology 1994; 1: 279–287
   PubMedGoogle Scholar
• van de Winkel J. G. J., Anderson C. L. Biology of human Immunoglobulin G Fc receptors. J. Leukocyte Biol. 1991; 49: 551–524
   Google Scholar
• Looney R. J., Abraham G. N., Anderson C. L. Human monocytes and U937 cells bear two distinct Fc receptors for IgG. J. Immunol. 1986; 136: 164–1647
   PubMedGoogle Scholar
• Haagen I. A., Geerars A. J. G., Clark M. R., van de Winkel J. G. J. Interaction of human monocyte Fcγ receptors with rat IgG2b: identification of a new polymorphism. J. Immunol. 1994, in press, Feb. 1995
   Web of Science ®Google Scholar
• Koolwijk P., van de Winkel J. G. J., Otten I., Bast B. J. E.G. Human monocyte-mediated cytotoxicity towards erythrocytes induced by hybrid mouse monoclonal antibodies: effect of antibody binding valency on IgG-FcγR interaction. Immunology 1992; 75: 336–342
   PubMed Web of Science ®Google Scholar
• Ferran C., Sheehan K., Dy M., Schreiber R., Merite S., Landais P., Noel L. H., Grau G., Bluestone J., Bach J. F., Chatenoud L. Cytokine-related syndrome following injection of anti-CD3 monoclonal antibody: further evidence for transient in vivo Tcell activation. Eur. J. Immunol. 1990; 20: 509–515
   PubMed Web of Science ®Google Scholar
• Haagen I. A., Geerars A. J., De Lau W. B., Clark M. R., van de Griend R. J., Bast E. J. E.G., De Gast B. C. Killing of autologous B-lineage malignancy using CD3×CD19 bispecific monoclonal antibody in end stage leukemia and lymphoma. Blood 1994; 84: 556–563
   PubMed Web of Science ®Google Scholar
• Spits H., Schooten W. V., Keizer H., van Seventer G., van de Rijn M., Terhorst C., De Vries J. E. Alloantigen recognition is preceded by nonspecific adhesion of cytotoxic T cell and target cells. Science 1986; 232: 403–405
   PubMed Web of Science ®Google Scholar
• Krensky A. M., Robbins E., Springer T. A., Burakoff S. J. LFA-1, LFA-2 and LFA-3 antigens are involved in CTL-target conjugation. J. Immunol. 1984; 132: 2180–2182
   PubMed Web of Science ®Google Scholar
• Miedema F., Tromp J. F., van het Veer N I. B., Poppema S., Melief C. J. M. Lymphocyte function-associated antigen 1 (LFA-1) is a marker of mature (immunocompetent) lymphoid cells. A survey of lymphoproliferative diseases in man. Leukemia Res. 1985; 9: 1099–1104
   PubMed Web of Science ®Google Scholar
• De Boer M., Parren P., Dove J., Ossendorp F., van de Horst G., Reeder J. Functional characterization of a novel anti-B7 monoclonal antibody. Eur. J. Immunol. 1992; 22: 3071–3075
   PubMed Web of Science ®Google Scholar
• Linsley P. S., Clark E. A., Ledbetter J A. T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB1. Proc. Natl. Acad. Sci. USA 1990; 87: 5031–5035
   PubMed Web of Science ®Google Scholar
• Azuma M., Cayabyab M., Phillips J. H., Lanier L. Requirements for CD28-dependent T cell-mediated cytotoxicity. J. Immunol. 1993; 150: 2091–2101
   PubMed Web of Science ®Google Scholar
• Chen L., Ashe S., Brady W. A., Hellström I., Hellström K. E., Ledbetter J. A., McGowan P., Linsley P. S. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 1992; 71: 1093–1102
   PubMed Web of Science ®Google Scholar
• Hui K., Grosveld F., Festenstein H. Rejection of trans-plantable AKR leukaemia cells following MHC DNA-mediated transformation. Nature 1984; 311: 770–752
   Web of Science ®Google Scholar
• Medeiros L. J., Weiss L. M., Picker L. J., Clayberger C., Horning S. J., Krensky A. M., Warnke R. A. Expression of LFA-1 in Non-Hodgkin's lymphoma. Cancer 1989; 63: 255–259
   PubMed Web of Science ®Google Scholar
• Horst E., Meijer C. J. L.M., Radaszkiewicz T., Ossekoppele G. J., van Krieken J. H. J.M., Pals S. T. Adhesion molecules in the prognosis of diffuse large-cell lymphoma expression of a lymphocyte homing, receptor (CD44), LFA-1(CD11 a/18), and ICAM-1 (CD54). Leukemia 1990; 4: 595–599
   PubMed Web of Science ®Google Scholar
• Stauder R., Greil R., Schulz T. F., Thaler J., Gattinger C., Radaskiewicz T., Dierich M. P., Huber H. Expression of leucocyte function-associated antigen-1 and 7F7-antigen, an adhesion molecule related to intercellular adhesion molecule-1 (ICAM-I) in non-Hodgkin lymphomas and leukemias: possible influence on growth pattern and leukaemic behaviour. Clin. Exp. Immunol. 1989; 77: 234–238
   PubMed Web of Science ®Google Scholar
• Delabie J., Ceuppens J. L., Vandenberghe P., De Boer M., Coorevits L., De Wolf-Peeters C. The B7/BB1 antigen is expressed by Reed-Sternberg cells of Hodgkin's disease and contributes to the stimulating capacity of Hodgkin's disease-derived cell lines. Blood 1993; 82: 2845–2852
   PubMed Web of Science ®Google Scholar
• Freeman G. J., Freedman A. S., Segil J. M., Lee G., Whitman J. F., Nadler L. M. B7, anew member of the Ig super-family with unique expression on activated and neoplastic B cells. J. Immunol. 1989; 143: 2714–2722
   PubMed Web of Science ®Google Scholar
• Safrit J. T., Bonavida B. Hierarchy of in vitro sensitivity and resistance of tumor cells to cytotoxic effector cells, cytokines, drugs and toxins. Cancer Immunol. Immunother. 1992; 34: 321–328
   PubMed Web of Science ®Google Scholar
• Horning S. J. Treatment approaches to the low-grade lymphomas. Blood 1994; 83: 881–884
   PubMed Web of Science ®Google Scholar
• Nelson H. Targeted Cellular Immunotherapy with Bifunctional Antibodies. Cancer Cells 1991; 3: 163–172
   PubMed Web of Science ®Google Scholar
• Haagen I. A., De Lau W. B. M., Bast B. J. E.G., Geerars A. J. G., Clark M. R., De Gast B. C. Unprimed CD4+ and CD8+ T cells can be rapidly activated by a CD3×CD19 bispecific antibody to proliferate and become cytotoxic. Cancer Immunol. Immunother. 1994; 39: 391–396
   PubMed Web of Science ®Google Scholar
• Clark E. A., Ledbetter J. A. How B and T cells talk to each other. Nature 1994; 367: 425–428
   PubMed Web of Science ®Google Scholar
• Weiner G. J. Bispecific IgG and IL-2 therapy of a syngenic B-cell lymphoma in immunocompetent mice. Int. J Cancer 1992; 7: 63–66
   Google Scholar
• Slaper-Cortenbach I. C. M., Admiraal L. G., van Leeuwen E. F., Kerr J. M., von dem Borne A. E. G., Kr, Tetteroo A. T. Effective purging of bone marrow by a combination of im-munorosette depletion and complement lysis. Exp. Hematol. 1990; 18: 49–54
   PubMed Web of Science ®Google Scholar
• Bast R. C., De Fabritiis P., Lipton J., Gelber R., Maver C., Nadler L., Sallen S., Ritz J. Elimination, of malignant clonogenic cells from human bone marrow using multiple monoclonal antibodies and complement. Cuncer Res. 1985; 45: 499–503
   PubMed Web of Science ®Google Scholar
• Rosenfeld C., Goutner A., Choquet C., Venuat A. M., Pico J. L. Phenotypic characterisation of a unique non-T, non-B acute lymphoblastic leukaemia cell line. Nature 1977; 267: 841–843
   PubMed Web of Science ®Google Scholar
• Haagen I. A., Geerars A. J. G., De Lau W. B. M., Bast E. J. E.G, De Gast G. C. The efficacy of bispecific antibody in a clonogenic assay; the effect of repeated addition of BsAb and IL.-2. Blood 1995, in press
   PubMed Web of Science ®Google Scholar
• Kroesen B. J., Haar A. T., Spakman H., Willemse P., Sleijfer D., Th, De Vries E. G. E., Mulder N. H., Berendsen H. H., Limburg P. C., The T. H., De Letj L. Local antitumor treatment in carcinoma patients with bispecific-monoclonal-antibody-redirected T cells. Cancer Immunol. Immunother. 1993; 37: 400–407
   PubMed Web of Science ®Google Scholar
• De Gast G. C., Haagen I. A., van Houten A. A., Klein S., Duits A. J., De Weger R. A., Vroom M., Th, Clark M. R., Philips J., Geerars A. J. G., De Lau W. B. M., Bast E. J. E.G. T cell activation after intravenous administration of CD3×CD19 bispecific antibody in patients with B cell malignancy. A phase I study. Br. J. Haemat. 1995, submitted
   Google Scholar
• Roosnek E. E., van Lier R. A., Aarden L. A. Two monoclonal anti-LCD3 antibodies can induce different events in human T lymphocyte activation. Eur. J. Immunol. 1987; 17: 1507–1510
   PubMed Web of Science ®Google Scholar
• Bohlen H., Hopff T., Manzke O., Engert A., Kube D., Wickramanayake P. D., Diehl V., Tesch H. Lysis of malignant B cells from patients with B-chronic lymphocytic leukemia by autologous T cells activated with CD3 × CD 19 bispecific antibodies in combination with bivalent CD28 antibodies. Blood 1993; 82: 1803–1812
   PubMed Web of Science ®Google Scholar
• Pohl C., Denfeld R., Renner C., Jung W., Bohlen H., Sahin U., Hombach A., van Lier R., Schwonzen M., Diehl V., Pfreundschuh M. CD30-antigen-specific targeting and activation of T cells via murine bispecific monoclonal antibodies against CD3 and CD28: potential use for treatment of Hodgkin's lymphoma. Int. J. Cancer 1993; 54: 820–827
   PubMed Web of Science ®Google Scholar
• Jung G., Freimann U., Marschall Z. V., Reisfeld R. A., Wilmanns W. Target cell-induced T cell activation with bi- and trispecific antibody fragments. Eur. J. Immunol. 1991; 21: 2431–2435
   PubMed Web of Science ®Google Scholar
• Schwartz R. H. Costimulation of T lymphocytes: The role of CD28, CLTA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 1992; 71: 1065–1068
   PubMed Web of Science ®Google Scholar
• Freedman A. S., Freeman G. J., Rhynhart K., Nadler L. M. Selective induction of B7/BB1 on interferon-y stimulated monocytes: a potential mechanism for amplification of T cell activation through the CD28 pathway. Cell. Immunol. 1991; 137: 429–437
   PubMed Web of Science ®Google Scholar
• Mueller D. L., Jenkins M. K., Schwartz R. H. Clonal expansion versus functional clonal inactivation: A costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Ann. Rev. Immunol. 1989; 7: 445–480
   PubMed Web of Science ®Google Scholar
• Beverly B., Kang S. M., Lenardo M. J., Schwartz R. H. Reversal of in vitro T cell clonal anergy by IL-2 stimulation. Int. Immunol. 1992; 4: 661–671
   PubMed Web of Science ®Google Scholar
• Kang S. M., Beverly B., Tran A. C., Brorson K., Schwartz R. H., Lenardo M. J. Transactivation by AP-1 is a molecular target of T cell clonal anergy. Science 1992; 257: 1134–1138
   PubMed Web of Science ®Google Scholar
• Young J. W., Koulova L., Soergel S. A., Clark E. A., Steinman R. M., Dupont B. The B7/BB1 antigen provides one of several costimulatory signals for the activation of CD4+ T lymphocytes by human blood dendritic cells in vitro. J. Clin. Invest. 1992; 90: 229–237
   PubMed Web of Science ®Google Scholar
• Vlasveld L. T., Hekman A., Vyth-Dreese F. A., Rankin E. M., Scharenberg J. G. M., Voordouw A. C., Sein J. J., Dellemijn T. A. M., Rodenhuis S., Melief C. J. M. A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part II: immunological aspects. Br. J. Cancer 1993; 68: 559–567
   PubMed Web of Science ®Google Scholar
• Foa R., Guarini A., Gansbacher B. IL2 treatment for cancer: from biology to gene therapy. Br. J. Cancer 1992; 66: 992–998
   PubMed Web of Science ®Google Scholar
• Siegel J. P., Puri R. K. Interleukin-2 toxicity. J. Clin. Oncol. 1991; 9: 694–704
   PubMed Web of Science ®Google Scholar
• Janssen R. A. J., Mulder N. H., The T. H., De Leij L. The immunobiological effects of interleukin-2 in vivo. Cancer Immunol. Immunother. 1994; 39: 207–216
   PubMed Web of Science ®Google Scholar
• Konrad M. W., Hemstreet G., Hersh E. M., Mansell P. W. A., Mertelsmann R., Kolitz J. E., Bradley E. C. Pharmacokinetics of recombinant Interleukin 2 in humans. Cancer Res. 1990; 50: 2009–2017
   PubMed Web of Science ®Google Scholar
• Ratain M. J., Priest E. R., Janisch L., Vogelzang N. J. A phase I study of subcutaneous recombinant interleukin-2 and interferon alfa-2a. Cancer 1993; 71: 2371–2376
   PubMed Web of Science ®Google Scholar
• Janssen R. A. I., Buter J., Straatsma E., Heijn A. A., Sleijfer D., Th, De Vries E. G. E., Mulder N. H., The H., De Leij L. HLA-Dr-expressing CD8-bright cells are only temporarily present in the circulation during subcutaneous recombinant interleukin-2 therapy in renal cell carcinoma patients. Cancer Immunol. Immunother. 1993; 36: 198–204
   PubMed Web of Science ®Google Scholar
• Bohlen H., Manzke O., Patel B., Moldenhauer G., Dörken B., von Fliedner V., Diehl V., Tesch H. Cytolysis of leukemic B-cells by T-cells activated via two bispecific antibodies. Cancer Res. 1993; 53: 4310–4314
   PubMed Web of Science ®Google Scholar
• June C. H., Ledbetter J. A., Linsley P. S., Thompson C. B. Role of the CD28 receptor in T-cell activation. Immunol. Today 1990; 11: 211–216
   PubMedGoogle Scholar
• Martin P. J., Ledbetter J. A., Morishita Y., June C. H., Beatty P. G., Hansen J. A. A 44 kilodalton cell surface homodimer regulates interleukin 2 production by activated human T lymphocytes. J. Immunol. 1986; 136: 3282–3287
   PubMed Web of Science ®Google Scholar
• Renner C., Jung W., Sahin U., Denfeld R., Pohl C., Trümper L., Hartmann F., Diehl V., van Lier R., Pfreundschuh M. Cure of xenografted human tumors by bispecific monoclonal antibodies and human T cells. Science 1994; 264: 833–835
   PubMed Web of Science ®Google Scholar
• Fleischer B. Acquisition of specific cytotoxic activity by human T4+ T lymphocytes in culture. Nature 1984; 308: 365–367
   PubMed Web of Science ®Google Scholar
• Garrido M. A., Perez P., Titus J. A., Valdayo M. J., Winkler D. F., Barbieri S. A., Wunderlich J. R., Segal D. M. Targeted cytotoxic cells in human peripheral blood lymphocytes. J. Immunol. 1990; 144: 2891–2898
   PubMed Web of Science ®Google Scholar
• Nishimura T., Nakamura Y., Takeuchi Y., Tokuda Y., Iwasawa M., Kawasaki A., Okumura K., Habu S. Generation, propagation, and targeting of human CD4+ helper/killer T cells induced by anti-CD3 monoclonal antibody plus recombinant IL-2. J. Immunol. 1992; 148: 285–291
   PubMed Web of Science ®Google Scholar
• Smith M. J., Norihisa Y., Ortaldo J. R. Multiple cytolytic mechanisms displayed by activated human peripheral blood T cell subsets. J. Immunol. 1992; 148: 55–62
   PubMed Web of Science ®Google Scholar
• Qian J. H., Titus J. A., Andrew S. M., Mezzanzanica D., Garrido M. A., Wunderlich J. R., Segal D. M. Human peripheral blood lymphocytes targeted with bispecific antibodies release cytokines that are essential for inhibiting tumor growth. J. Immunol. 1991; 146: 3250–3256
   PubMed Web of Science ®Google Scholar
• Damle N. K., Mohagheghpour N., Hansen J. A., Engleman E. G. Alloantigen-specific cytotoxic and suppressor T lymphocytes are derived from phenotypically distinct precursors. J. Immunol. 1983; 131: 2296–2300
   PubMed Web of Science ®Google Scholar
• van Lier R. A. W., Boot J. H. A., De Groot E. R., Aarden L. A. Induction of T cell proliferation with anti-CD3 switch-variant monoclonal antibodies: effects of heavy chain isotype in monocyte-dependent systems. Eur. J. Immunol. 1987; 17: 1599–1604
   PubMed Web of Science ®Google Scholar
• Parren P. W. H.I., Warmerdam P. A. M., Boeije L. C. M., Arts J., Westerdaal N. A. C., Vlug A., Capel P. J. A., Aarden L. A., van de Winkel J. G. J. On the interaction of IgG subclasses with the low affinity FcγRIIa (CD32) on human monocytes, neutrophils, and platelets. J. Clin. Invest. 1992; 90: 1537–1546
   PubMed Web of Science ®Google Scholar
• Hoffman T., Tripathi A. K., Lee Y. L., Bonvini E., Golding B. Inflammatory mediator release from human monocytes via immobilized Fc receptors. Transplantation 1992; 54: 343–346
   PubMed Web of Science ®Google Scholar
• Frenken L. A. M., Koene R. A. P., Tax W. J. M. The role of antibody isotype in IFN-y and IL-2 production during anti-CD3-induced T cell proliferation. Transplantation 1991; 51: 881–887
   PubMed Web of Science ®Google Scholar
• Krutmann J., Kirnbauer R., Köck A., Schwarz T., Schöpf E., May L. T., Sehgal P. B., Luger T. A. Cross-linking Fc receptors on monocytes triggers IL-6 production: Role in anti-CD3-induced T cell activation. J. Immunol. 1990; 145: 1337–1342
   PubMed Web of Science ®Google Scholar
• Tax W. J. M., Holtrop S., Koene R. A. P. Clinical implications of the polymorphic interaction of murine IgG2b and IgG1 with human Fc receptors. Transplant Immunol. 1993; 1: 252–254
   Google Scholar
• Greenman J., Hogg N., Nikoletti S., Slade C., Stevenson G., Glennie M. Comparitive efficiencies of bispecific F(ab'y)2 and chimeric mouse/human IgG antibodies in recruiting cellular effector for cytotoxicity via Fcy receptors. Cancer Immunol. Immunother. 1992; 34: 361–369
   PubMed Web of Science ®Google Scholar
• Press O. W., Appelbaum F., Ledbetter J. A., Martin P. J., Zarling J., Kidd P., Donnall Thomas E. Monoclonal antibody 1F5 (anti-CD20) scrotherapy of human B cell lymphomas. Blood 1987; 69: 584–591
   PubMed Web of Science ®Google Scholar
• Allebes W., Knops R., Herold M., Huber C., Haanen C., Capel P. Immunotherapy with monoclonal anti-idiotypic antibodies: tumour reduction and lymphokine production. Leukemia Res. 1991; 15: 215–222
   PubMed Web of Science ®Google Scholar
• Riechmann L., Clark M., Waldmann H., Winter G. Reshaping human antibodies for therapy. Nature 1988; 332: 323–327
   PubMed Web of Science ®Google Scholar
• Bruynck A., Seemann G., Bosslet K. Characterisation of a humanised bispecific monoclonal antibody for cancer therapy. Br. J. Cancer 1993; 67: 436–440
   PubMed Web of Science ®Google Scholar
• Phelps J. L., Beidler D. E., Jue R. A., Unger B. W., Johnson M. J. Expression and characterization of a chimeric bi-functional antibody with therapeutic applications. J. Immunol. 1990; 145: 1200–1204
   PubMed Web of Science ®Google Scholar
• Shalaby M. K., Shepaled H. M., Presta L., Rodrigues M. L., Beverly P. C. L., Feldmann M., Carter P. Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncogene. J. Exp. Med. 1992; 175: 217–225
   PubMed Web of Science ®Google Scholar